课题基金 / 基金详情

Aiming at a novel target in endotoxin-associated lung damage: The Ig domain 3 of ICAM-1

Aiming at a novel target in endotoxin-associated lung damage: The Ig domain 3 of ICAM-1
针对内毒素相关肺损伤的新靶点：ICAM-1 的 Ig 结构域 3
批准号：
477251
负责人：
Zhang Haibo
金额：
$7.29万
依托单位：
Unity Health Toronto
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
已结题
起止时间：
2022-10-01 至 2023-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=477251&lang=en
关键词：
Microbiology& Infection Diseases

项目摘要

项目成果

Zhang Haibo的其他基金

相关文献

中文摘要
翻译
急性肺损伤（ALI）是危重症患者死亡的主要原因。脓毒症是一种危及生命的感染并发症，是急性呼吸道感染的主要原因。大约50%的脓毒症患者与脂多糖（LPS）有关
英文摘要
Acute lung injury (ALI) is a leading cause of death in critically ill patients. Sepsis, a life-threatening complication of infection, is the major cause of ALI. Approximately 50% of patients with sepsis are implicated with the lipopolysaccharide (LPS), a
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Aiming at a new target in endotoxin-associated lung damage: The Ig domain 3 of ICAM-1
  • 批准号：
    479050
  • 项目类别：
    Operating Grants
  • 资助金额：
    $71.56万
  • 财政年份：
    2023
  • 负责人：
    Zhang Haibo
  • 依托单位：
    Unity Health Toronto
COVID-19 Variant Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
Sex as a Biological Variable Supplement - Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)
Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2)